ArticleJournal of controlled release : official journal of the Controlled Release Society2015
Sequential delivery of angiogenic growth factors improves revascularization and heart function after myocardial infarction.
Article in Journal of controlled release : official journal of the Controlled Release Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 133 citations in OpenAlex.
- Decellularized cardiac ECM: A tissue-specific bioactive platform for drug release and cell delivery.Journal of controlled release : official journal of the Controlled Release Society · 2026Review
- Phased affinity-controlled delivery of vascular endothelial growth factor, fibroblast growth factor-2, and platelet derived growth factor enhances in vitro angiogenesis.Journal of controlled release : official journal of the Controlled Release Society · 2026Article
- Heparin-Based Biomaterials for Sustained Release of Growth Factors for Bone Tissue Engineering and Regeneration.Journal of functional biomaterials · 2026Review
- Fibrin scaffolds for angiogenesis in soft tissue models: a systematic review.Bioactive materials · 2026Review
- 3D-printed functionalized strontium-silk fibroin-hydroxyapatite scaffolds facilitate bone regeneration via immunomodulatory and sequential angiogenic-osteogenic coupling.Bioactive materials · 2026Article
- Smart coacervate microdroplets: biomimetic design, material innovations, and emerging applications in biomacromolecule delivery.Bioactive materials · 2025Review
- Coacervate-Based Delivery Systems: Bridging Fundamentals and Applications.ACS applied materials & interfaces · 2025Review
- Applying Computational Protein Design to Engineer Affibodies for Affinity-controlled Delivery of Vascular Endothelial Growth Factor and Platelet-Derived Growth Factor.Biomacromolecules · 2025Article
- Regulation of CRISPR trans-cleavage activity by an overhanging activator.Nucleic acids research · 2025Article
- A Review on Bone Tumor Management: Cutting-Edge Strategies in Bone Grafting, Bone Graft Substitute, and Growth Factors for Defect Reconstruction.Orthopedic research and reviews · 2025Review
- Unraveling and Harnessing the Immune Response at the Cell-Biomaterial Interface for Tissue Engineering Purposes.Advanced healthcare materials · 2024Review
- Developing Porous Fibrin Scaffolds with Tunable Anisotropic Features to Direct Myoblast Orientation.Tissue engineering. Part C, Methods · 2024Article
- The role of cardiac pericytes in health and disease: therapeutic targets for myocardial infarction.Nature reviews. Cardiology · 2024Review
- Therapeutic angiogenesis based on injectable hydrogel for protein delivery in ischemic heart disease.iScience · 2023Review
- Cytokine storm: behind the scenes of the collateral circulation after acute myocardial infarction.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2022Review
- Research Advances of Injectable Functional Hydrogel Materials in the Treatment of Myocardial Infarction.Gels (Basel, Switzerland) · 2022Review
- Macrophage Infiltration Reduces Neurodegeneration and Improves Stroke Recovery after Delayed Recanalization in Rats.Oxidative medicine and cellular longevity · 2022Article
- Myocardial protection by heparin-based coacervate of FGF10.Bioactive materials · 2021Article
- Biologics and their delivery systems: Trends in myocardial infarction.Advanced drug delivery reviews · 2021Review
- A perfusable, multifunctional epicardial device improves cardiac function and tissue repair.Nature medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Treatment of ischemia through therapeutic angiogenesis faces significant challenges. Growth factor (GF)-based therapies can be more effective when concerns such as GF spatiotemporal presentation, bioactivity, bioavailability, and localization are addressed. During angiogenesis, vascular endothelial GF (VEGF) is required early to initiate neovessel formation while platelet-derived GF (PDGF-BB) is needed later to stabilize the neovessels. The spatiotemporal delivery of multiple bioactive GFs involved in angiogenesis, in a close mimic to physiological cues, holds great potential to treat ischemic diseases. To achieve sequential release of VEGF and PDGF, we embed VEGF in fibrin gel and PDGF in a heparin-based coacervate that is distributed in the same fibrin gel. In vitro, we show the benefits of this controlled delivery approach on cell proliferation, chemotaxis, and capillary formation. A rat myocardial infarction (MI) model demonstrated the effectiveness of this delivery system in improving cardiac function, ventricular wall thickness, angiogenesis, cardiac muscle survival, and reducing fibrosis and inflammation in the infarct zone compared to saline, empty vehicle, and free GFs. Collectively, our results show that this delivery approach mitigated the injury caused by MI and may serve as a new therapy to treat ischemic hearts pending further examination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.